ISRCTN70821789已完成未知
A double-blind, multicentre, randomized, parallel-group trial to compare efficacy and safety of GA-AT0719 versus simethicone in the treatment of functional abdominal bloating and distention
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Adults between 18 and 65 years of age
- •2. Caucasian race
- •3. Suffering from functional abdominal bloating and distention
排除标准
- •1. Pregnant women or breastfeeding
- •2. Unwilling to sign the informed consent form
- •3. Allergy to one of the product ingredients
- •4. Unable to come to the study visits
- •5. Health status not allowing participation in the study
- •6. Diabetic patients
- •7. Patients diagnosed with celiac disease
- •8. Patients treated with antibiotics 2 weeks prior to the Hydrogen Breath Test schedule
- •9. Patients who were using purgatives within 2 weeks prior to the Hydrogen Breath Test
研究者
相似试验
进行中（未招募）
1 期
Study of safety and efficacy of Hercules versus Herceptin® in patients with breast cancerHuman Epidermal Growth Factor Receptor 2 positive (HER2+) metastatic breast cancer (MBC)MedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2011-001965-42-BGMYLAN GmbH600
进行中（未招募）
1 期
Study to assess the efficacy and safety of investigational product, P-3074 cutaneous spray, solution, in the treatment of male pattern baldness.Androgenetic alopeciaEUCTR2015-002877-40-DEPolichem S.A.458
进行中（未招募）
1 期
Study to assess the efficacy and safety of investigational product, P-3074 cutaneous spray, solution, in the treatment of male pattern baldness.MedDRA version: 19.0Level: PTClassification code 10068168Term: Androgenetic alopeciaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersAndrogenetic alopeciaEUCTR2015-002877-40-ESPolichem S.A.450
进行中（未招募）
1 期
A multicentre, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of once daily oral dosing of GW501516 (2.5 mg, 5 mg and 10 mg) over 12 weeks in subjects withprimary hypercholesterolemia on background statin therapy.primary hypercholesterolemiaMedDRA version: 8.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2006-002911-28-NLGlaxoSmithKline R&D
进行中（未招募）
不适用
A multicentre, randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study to evaluate the efficacy, safety and tolerability of once daily oral dosing of GW501516 (2.5 mg, 5 mg and 10 mg) over 12 weeks in subjects withprimary hypercholesterolemia on background statin therapy.primary hypercholesterolemiaMedDRA version: 8.1Level: LLTClassification code 10020604Term: HypercholesterolemiaEUCTR2006-002911-28-CZGlaxoSmithKline R&D192